FDMT — 4D Molecular Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.67bn
- $1.38bn
- $20.72m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -49.3 | -56.7 | -71.3 | -107 | -101 |
Depreciation | |||||
Non-Cash Items | 11.3 | 5.05 | 16.2 | 19.7 | 20.2 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.259 | -0.711 | -15.5 | -1.34 | 0.63 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -36.7 | -50.9 | -69.1 | -86.7 | -75.8 |
Capital Expenditures | -3.2 | -1 | -9.11 | -11.5 | -2.77 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | -164 | -5.51 | 118 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -3.2 | -1 | -173 | -17.1 | 116 |
Financing Cash Flow Items | -2.27 | — | — | -0.468 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | -2.19 | 279 | 118 | 3.08 | 157 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -42.1 | 227 | -124 | -101 | 197 |